Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Blueweave Consulting | PRODUCT CODE: 1208598

Cover Image

PUBLISHER: Blueweave Consulting | PRODUCT CODE: 1208598

Regenerative Medicine Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Product ; By Material ; By Application ; By End User ; By Region

PUBLISHED:
PAGES: 240 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 4850
Unprintable PDF (Group License)
USD 5750
PDF (Enterprise License)
USD 8150

Add to Cart

Global Regenerative Medicine Market Size Booming to Reach USD 73.5 Billion by 2029

Global regenerative medicine market is flourishing owing to rising investments in regenerative medicine research, expansion of the regenerative medicine market, and rising prevalence of genetic disorders, cancer, and chronic diseases.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated global regenerative medicine market size at USD 12.3 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global regenerative medicine market size to grow at a significant CAGR of 30.2% reaching a value of USD 73.5 billion by 2029. The rise in the prevalence of musculoskeletal diseases, oncological disorders, and dental disorders is the primary factor driving the growth of the regenerative medicine market. Another factor driving the market's expansion is an increase in the use of regenerative medicine products and technological advancements in stem cell-based therapies, which have revolutionized the way researchers view regenerative medicine. Many businesses are increasing their market presence to expand into new markets.

Global Regenerative Medicine Market - Overview

Organs and tissues that have been harmed by disease, aging, or trauma can be repaired, replaced, or regenerate with the help of regenerative medicines. These medicines are used to treat a range of degenerative illnesses, such as orthopedic, cardiovascular, and dermatological conditions. They function by making cells and tissues functional once more. Stem cells are more important in this context because they can divide and differentiate.

Opportunity: Increasing acceptance of cancer immunotherapy products

Normal cells undergo a multi-stage process that typically starts with a precancerous lesion and progresses to malignant tumors before becoming tumor cells, which is how cancer is brought on. The interaction of a person's hereditary factors results in these changes. Cancer is a leading cause of death worldwide, killing about 10 million people. A correct cancer diagnosis is essential for appropriate and efficient treatment because each type of cancer necessitates a different treatment strategy. Surgery, radiotherapy, and chemotherapy are frequently used to treat cancer. Because hematopoietic stem or more developed cells naturally can target and eradicate disease cells, cancer immunotherapy using regenerative medicine has the advantage of being able to do so. It also aids in the development of effective treatments by providing a better understanding of cancer cells. As a result, rising cancer treatment product demand, combined with rising disease prevalence, will create opportunities for market expansion.

Challenge: Costly treatments

For those with serious illnesses and terminal illnesses, gene and cell therapies represent a significant advance in medicine. These treatments are changing how diseases are treated and controlled. Even though these treatments are highly effective at saving lives, demand for them is lower than anticipated. This is due to the expensive nature of these treatments, which is restricting the market growth.

Impact of COVID-19 on Global Regenerative Medicine Market

The COVID-19 pandemic affected nearly all industries in 2020. Different segments of the regenerative medicine market were affected differently by the pandemic. The demand for tissue engineering was negative, whereas the demand for gene therapy was strong due to consistent sales of its rare disease therapeutics. Platelet-Rich Plasma (PRP) demand has decreased.

Global Regenerative Medicine Market - By Material

Global regenerative medicine market is segmented by material into Synthetic Material, Biodegradable Synthetic Polymers, scaffolds, and others. Biodegradable synthetic polymers, scaffolds, materials for artificial vascular grafts, and hydrogels are examples of synthetic material subcategories. The next two types of biologically derived material are collagen and xenogeneic material. Additional types of genetically engineered material include deoxyribonucleic acid, transfection vectors, genetically modified cells, three-dimensional polymer technology, transgenic, fibroblast, neural stem cell, and gene-activated matrices. Pharmaceuticals are divided into two categories: small molecules and biologics.

Competitive Landscape:

Global regenerative medicine market is fiercely competitive. Prominent players in the market include Aspect Biosystems, Amgen, Inc., Medtronic plc, AstraZeneca, Novartis AG, Smith & Nephew plc, MiMedx Group, Baxter, 3M, Athersys Inc, Cryo Life Inc, Integra Life Sciences, Isto Biologics, Medtronic Plc, Organogenesis, Stryker Corporation, US Stem Cell Inc, and Zimmer Biomet Holdings Inc. These companies use various strategies, including increasing investments in their R&D activities, mergers, and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in global regenerative medicine market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Regenerative Medicine Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Regenerative Medicine Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Product Code: BWC23083

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Regenerative Medicine Market Insights

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. DROC Analysis
    • 3.1.2. Growth Drivers
      • 3.1.2.1. Rise in Prevalence of Musculoskeletal Diseases, Oncological Disorders, and Dental Disorders
      • 3.1.2.2. Rise in Adoption of Regenerative Medicine Products
      • 3.1.2.3. Rise in Monitoring Devices and Surgical Technologies
    • 3.1.3. Restraints
      • 3.1.3.1. Lack of Skilled Professionals
    • 3.1.4. Opportunities
      • 3.1.4.1. Technological Advancement
      • 3.1.4.2. Increasing Investment in Development of Innovative Medicines
    • 3.1.5. Challenges
      • 3.1.5.1. Stringent Regulatory Framework
  • 3.2. Technology Advancements/Recent Developments
  • 3.3. Regulatory Framework
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of New Entrants
    • 3.4.4. Threat of Substitutes
    • 3.4.5. Intensity of Rivalry

4. Global Regenerative Medicine Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Million)
  • 4.2. Market Share & Forecast
    • 4.2.1. By Product
      • 4.2.1.1. Cell Therapy
      • 4.2.1.2. Gene Therapy
      • 4.2.1.3. Tissue Engineering
      • 4.2.1.4. Small Molecule & Biologic
      • 4.2.1.5. Others
    • 4.2.2. By Material
      • 4.2.2.1. Synthetic Material
      • 4.2.2.2. Biodegradable Synthetic Polymer
      • 4.2.2.3. Scaffold
      • 4.2.2.4. Others
    • 4.2.3. By Application
      • 4.2.3.1. Cardiovascular
      • 4.2.3.2. Oncology
      • 4.2.3.3. Dermatology
      • 4.2.3.4. Musculoskeletal
      • 4.2.3.5. Others
    • 4.2.4. By End User
      • 4.2.4.1. Hospitals & Clinics
      • 4.2.4.2. Commercial Industries
      • 4.2.4.3. Government & Academic Research Institutes
    • 4.2.5. By Region
      • 4.2.5.1. North America
      • 4.2.5.2. Europe
      • 4.2.5.3. Asia Pacific (APAC)
      • 4.2.5.4. Latin America
      • 4.2.5.5. Middle East and Africa (MEA)

5. North America Regenerative Medicine Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product
    • 5.2.2. By Material
    • 5.2.3. By Application
    • 5.2.4. By End User
    • 5.2.5. By Country
      • 5.2.5.1. US
      • 5.2.5.1.1. By Product
      • 5.2.5.1.2. By Material
      • 5.2.5.1.3. By Application
      • 5.2.5.1.4. By End User
      • 5.2.5.2. Canada
      • 5.2.5.2.1. By Product
      • 5.2.5.2.2. By Material
      • 5.2.5.2.3. By Application
      • 5.2.5.2.4. By End User

6. Europe Regenerative Medicine Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Material
    • 6.2.3. By Application
    • 6.2.4. By End User
    • 6.2.5. By Country
      • 6.2.5.1. Germany
      • 6.2.5.1.1. By Product
      • 6.2.5.1.2. By Material
      • 6.2.5.1.3. By Application
      • 6.2.5.1.4. By End User
      • 6.2.5.2. UK
      • 6.2.5.2.1. By Product
      • 6.2.5.2.2. By Material
      • 6.2.5.2.3. By Application
      • 6.2.5.2.4. By End User
      • 6.2.5.3. Italy
      • 6.2.5.3.1. By Product
      • 6.2.5.3.2. By Material
      • 6.2.5.3.3. By Application
      • 6.2.5.3.4. By End User
      • 6.2.5.4. France
      • 6.2.5.4.1. By Product
      • 6.2.5.4.2. By Material
      • 6.2.5.4.3. By Application
      • 6.2.5.4.4. By End User
      • 6.2.5.5. Spain
      • 6.2.5.5.1. By Product
      • 6.2.5.5.2. By Material
      • 6.2.5.5.3. By Application
      • 6.2.5.5.4. By End User
      • 6.2.5.6. The Netherlands
      • 6.2.5.6.1. By Product
      • 6.2.5.6.2. By Material
      • 6.2.5.6.3. By Application
      • 6.2.5.6.4. By End User
      • 6.2.5.7. Belgium
      • 6.2.5.7.1. By Product
      • 6.2.5.7.2. By Material
      • 6.2.5.7.3. By Application
      • 6.2.5.7.4. By End User
      • 6.2.5.8. NORDIC Countries
      • 6.2.5.8.1. By Product
      • 6.2.5.8.2. By Material
      • 6.2.5.8.3. By Application
      • 6.2.5.8.4. By End User
      • 6.2.5.9. Rest of Europe
      • 6.2.5.9.1. By Product
      • 6.2.5.9.2. By Material
      • 6.2.5.9.3. By Application
      • 6.2.5.9.4. By End User

7. Asia Pacific Regenerative Medicine Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Material
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country
      • 7.2.5.1. China
      • 7.2.5.1.1. By Product
      • 7.2.5.1.2. By Material
      • 7.2.5.1.3. By Application
      • 7.2.5.1.4. By End User
      • 7.2.5.2. India
      • 7.2.5.2.1. By Product
      • 7.2.5.2.2. By Material
      • 7.2.5.2.3. By Application
      • 7.2.5.2.4. By End User
      • 7.2.5.3. Japan
      • 7.2.5.3.1. By Product
      • 7.2.5.3.2. By Material
      • 7.2.5.3.3. By Application
      • 7.2.5.3.4. By End User
      • 7.2.5.4. South Korea
      • 7.2.5.4.1. By Product
      • 7.2.5.4.2. By Material
      • 7.2.5.4.3. By Application
      • 7.2.5.4.4. By End User
      • 7.2.5.5. Australia & New Zealand
      • 7.2.5.5.1. By Product
      • 7.2.5.5.2. By Material
      • 7.2.5.5.3. By Application
      • 7.2.5.5.4. By End User
      • 7.2.5.6. Indonesia
      • 7.2.5.6.1. By Product
      • 7.2.5.6.2. By Material
      • 7.2.5.6.3. By Application
      • 7.2.5.6.4. By End User
      • 7.2.5.7. Malaysia
      • 7.2.5.7.1. By Product
      • 7.2.5.7.2. By Material
      • 7.2.5.7.3. By Application
      • 7.2.5.7.4. By End User
      • 7.2.5.8. Singapore
      • 7.2.5.8.1. By Product
      • 7.2.5.8.2. By Material
      • 7.2.5.8.3. By Application
      • 7.2.5.8.4. By End User
      • 7.2.5.9. Philippines
      • 7.2.5.9.1. By Product
      • 7.2.5.9.2. By Material
      • 7.2.5.9.3. By Application
      • 7.2.5.9.4. By End User
      • 7.2.5.9.5. By End User
      • 7.2.5.10. Vietnam
      • 7.2.5.10.1. By Product
      • 7.2.5.10.2. By Material
      • 7.2.5.10.3. By Application
      • 7.2.5.10.4. By End User
      • 7.2.5.11. Rest of APAC
      • 7.2.5.11.1. By Product
      • 7.2.5.11.2. By Material
      • 7.2.5.11.3. By Application
      • 7.2.5.11.4. By End User

8. Latin America Regenerative Medicine Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Material
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country
      • 8.2.5.1. Brazil
      • 8.2.5.1.1. By Product
      • 8.2.5.1.2. By Material
      • 8.2.5.1.3. By Application
      • 8.2.5.1.4. By End User
      • 8.2.5.2. Mexico
      • 8.2.5.2.1. By Product
      • 8.2.5.2.2. By Material
      • 8.2.5.2.3. By Application
      • 8.2.5.2.4. By End User
      • 8.2.5.3. Argentina
      • 8.2.5.3.1. By Product
      • 8.2.5.3.2. By Material
      • 8.2.5.3.3. By Application
      • 8.2.5.3.4. By End User
      • 8.2.5.4. Peru
      • 8.2.5.4.1. By Product
      • 8.2.5.4.2. By Material
      • 8.2.5.4.3. By Application
      • 8.2.5.4.4. By End User
      • 8.2.5.5. Colombia
      • 8.2.5.5.1. By Product
      • 8.2.5.5.2. By Material
      • 8.2.5.5.3. By Application
      • 8.2.5.5.4. By End User
      • 8.2.5.6. Rest of LATAM
      • 8.2.5.6.1. By Product
      • 8.2.5.6.2. By Material
      • 8.2.5.6.3. By Application
      • 8.2.5.6.4. By End User

9. Middle East & Africa Regenerative Medicine Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Material
    • 9.2.3. By Application
    • 9.2.4. By End User
    • 9.2.5. By Country
      • 9.2.5.1. Saudi Arabia
      • 9.2.5.1.1. By Product
      • 9.2.5.1.2. By Material
      • 9.2.5.1.3. By Application
      • 9.2.5.1.4. By End User
      • 9.2.5.2. UAE
      • 9.2.5.2.1. By Product
      • 9.2.5.2.2. By Material
      • 9.2.5.2.3. By Application
      • 9.2.5.2.4. By End User
      • 9.2.5.3. Qatar
      • 9.2.5.3.1. By Product
      • 9.2.5.3.2. By Material
      • 9.2.5.3.3. By Application
      • 9.2.5.3.4. By End User
      • 9.2.5.4. Kuwait
      • 9.2.5.4.1. By Product
      • 9.2.5.4.2. By Material
      • 9.2.5.4.3. By Application
      • 9.2.5.4.4. By End User
      • 9.2.5.5. South Africa
      • 9.2.5.5.1. By Product
      • 9.2.5.5.2. By Material
      • 9.2.5.5.3. By Application
      • 9.2.5.5.4. By End User
      • 9.2.5.6. Nigeria
      • 9.2.5.6.1. By Product
      • 9.2.5.6.2. By Material
      • 9.2.5.6.3. By Application
      • 9.2.5.6.4. By End User
      • 9.2.5.7. Egypt
      • 9.2.5.7.1. By Product
      • 9.2.5.7.2. By Material
      • 9.2.5.7.3. By Application
      • 9.2.5.7.4. By End User
      • 9.2.5.8. Rest of MEA
      • 9.2.5.8.1. By Product
      • 9.2.5.8.2. By Material
      • 9.2.5.8.3. By Application
      • 9.2.5.8.4. By End User

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Regenerative Medicine Company Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Regenerative Medicine Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. Aspect Biosystems,
  • 12.2. Amgen, Inc.,
  • 12.3. Medtronic plc,
  • 12.4. AstraZeneca,
  • 12.5. Novartis AG,
  • 12.6. Smith & Nephew plc,
  • 12.7. MiMedx Group,
  • 12.8. Baxter
  • 12.9. 3M
  • 12.10. Athersys Inc
  • 12.11. Cryo Life Inc
  • 12.12. Integra Life Sciences
  • 12.13. Isto Biologics
  • 12.14. Medtronic Plc
  • 12.15. Organogenesis
  • 12.16. Stryker Corporation
  • 12.17. US Stem Cell Inc
  • 12.18. Zimmer Biomet Holdings Inc
  • 12.19. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations

*Financial information in case of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!